Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference TranscriptSeeking Alpha • 11/17/25
Johnson & Johnson strengthens oncology portfolio with $3B Halda Therapeutics acquisitionProactive Investors • 11/17/25
Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJZacks Investment Research • 11/17/25
New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritisPRNewsWire • 11/17/25
Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda TherapeuticsBusiness Wire • 11/17/25
Why Is Johnson & Johnson (JNJ) Up 1.7% Since Last Earnings Report?Zacks Investment Research • 11/13/25
Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 TranscriptSeeking Alpha • 11/11/25
Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference TranscriptSeeking Alpha • 11/11/25
FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma ProgressionBenzinga • 11/07/25
Is a Market Correction Coming? Better Grab 5 of the Safest Dividend Kings Now24/7 Wall Street • 11/07/25
DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myelomaPRNewsWire • 11/06/25
FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorderPRNewsWire • 11/06/25
Johnson & Johnson to Participate in the Citi's 2025 Global Healthcare ConferenceBusiness Wire • 11/05/25